UG HEALTHCARE CORPORATIONLTD (SGX:8K7)
UG Healthcare 1H22 - Stability & Value Creeping Up
- UG Healthcare (SGX:8K7)'s 1H22 PATMI fell 67% y-o-y to S$21.2mil. Revenue/PATMI were within expectations at 52%/54% of our FY22e forecasts.
- Glove selling prices fell by more than 50% and glove production was disrupted in the three months of July to September 2021. We believe industry glove prices are still slipping in 1Q22, but at a slower pace of around 10% q-o-q to US$20-25.
- We maintain our FY22e earnings forecast for UG Healthcare.
- Some stability is creeping up in glove selling prices. Any rebound in prices will remain elusive due to the huge influx of nitrile capacity, especially from China.
- We raise our recommendation for UG Healthcare from ACCUMULATE to BUY.
The Positive
Stronger balance sheet.
- UG Healthcare's net cash in 1H21 was S$73.1mil (1H20: $32.5mil), boosted by free cash-flows of S$21.5mil. Net cash represents 43% of the market capitalisation.
The Negative
Further delay in new capacity.
- The new 1.2bn glove factory in Seremban will be delayed from March 2022 to May 2022. Construction work stopped from June to August due to lockdowns and labour shortages. It only resumed in mid-September. Meanwhile, the focus for the company will be on glove branding efforts and sourcing of new factory workers.
Outlook
- Glove prices especially for nitrile are still declining but at a slower pace. Chinese manufacturers remain the largest price disrupter in the industry prompting Malaysian peers to either match or come closer to the lower prices. The ample capacity in China is reflected by their short delivery times to meet customer orders.
- UG Healthcare can fare better than peers despite lower prices by:
- Outsourcing more customer orders to third party factories to take advantage of these lower factory prices;
- UG Healthcare enjoys higher prices as a distributor to end customers. Such end customers pay a premium due to the smaller order quantities of cartons or pellets;
- UG Healthcare is experiencing glove demand from new industries such as farming and beauty; and
- Emerging market customers are upgrading their quality standards as health awareness has risen significantly due to the pandemic. UG Healthcare’s exposure to emerging markets and latex gloves such as Brazil, China and Nigeria is around 45% of sales.
Upgrade UG Healthcare to BUY from ACCUMULATE with an unchanged target price of S$0.32
- We find valuations of UG Healthcare turning more attractive and the pace of decline in glove prices tapering off.
- See
- Our target price for UG Healthcare is unchanged at S$0.32 and pegged at a 30% discount to the Big 4 glove makers. This implies 5x FY22e P/E. We raise our recommendation for UG Healthcare from ACCUMULATE to BUY.
- We see value in UG Healthcare's share price as the company is trading below its book value of S$0.338 and 43% of the market capitalisation is net cash.
Paul Chew
Phillip Securities Research
|
https://www.stocksbnb.com/
2022-02-15
SGX Stock
Analyst Report
0.320
SAME
0.320
